NASDAQ · BTMD
Healthcare · Medical - Care Facilities
$1.42
Up+$0.09 (+6.34%)
Updated Aug 13, 2026, 6:33 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BTMD closed at $1.42 after 21 trading sessions, down 34.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.55 | $1.55 | $1.40 | $1.42 | 191.26K |
| Aug 11, 2026 | $1.54 | $1.60 | $1.515 | $1.54 | 59.87K |
| Aug 10, 2026 | $1.51 | $1.59 | $1.45 | $1.54 | 317.15K |
| Aug 7, 2026 | $1.66 | $1.74 | $1.46 | $1.48 | 357.38K |
| Aug 6, 2026 | $1.91 | $1.9199 | $1.54 | $1.63 | 704.97K |
| Aug 5, 2026 | $2.21 | $2.3499 | $2.155 | $2.26 | 81.36K |
| Aug 4, 2026 | $2.28 | $2.31 | $2.25 | $2.27 | 60.42K |
| Aug 3, 2026 | $2.28 | $2.31 | $2.19 | $2.29 | 127.21K |
| Jul 31, 2026 | $2.28 | $2.285 | $2.2201 | $2.25 | 78.56K |
| Jul 30, 2026 | $2.03 | $2.25 | $2.03 | $2.22 | 141.64K |
| Jul 29, 2026 | $2.23 | $2.36 | $1.98 | $2.04 | 660.98K |
| Jul 28, 2026 | $2.33 | $2.35 | $2.2216 | $2.24 | 63.07K |
| Jul 27, 2026 | $2.27 | $2.395 | $2.27 | $2.33 | 203.96K |
| Jul 24, 2026 | $2.24 | $2.30 | $2.22 | $2.28 | 196.41K |
| Jul 23, 2026 | $2.35 | $2.35 | $2.25 | $2.25 | 68.72K |
| Jul 22, 2026 | $2.53 | $2.53 | $2.34 | $2.35 | 45.01K |
| Jul 21, 2026 | $2.48 | $2.60 | $2.41 | $2.52 | 209.62K |
| Jul 20, 2026 | $2.42 | $2.55 | $2.335 | $2.49 | 209.81K |
| Jul 17, 2026 | $2.38 | $2.53 | $2.29 | $2.43 | 298.39K |
| Jul 16, 2026 | $2.215 | $2.395 | $2.19 | $2.38 | 320.62K |
| Jul 15, 2026 | $2.19 | $2.2699 | $2.1002 | $2.17 | 261.01K |
The latest Smart Investors Daily articles mentioning BTMD.
BTMD research
Company profile and research snapshot.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | B. Riley Securities | Neutral | — |
| Aug 7, 2026 | TD Cowen | Buy | — |
| Apr 16, 2026 | Truist Securities | Buy | — |
| Mar 12, 2026 | TD Cowen | Buy | — |
| Mar 12, 2026 | B. Riley Securities | Neutral | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock moved upwards by
Benzinga · Aug 10, 2026
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
Benzinga · Aug 7, 2026
TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.
SeekingAlpha · Aug 6, 2026
biote Corp. (BTMD) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDTCompany ParticipantsRobert Peterson - Interim CEO, CFO & Chief Business...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BTMD.
